Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer

You may not be if

• Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician
• Patients with moderate to high-risk disease as defined by D' Amico risk stratification and having at least one of the following:
• * Prostate-specific antigen (PSA) level \> 10 ng/ml
• * Gleason score \>= 7
• * Clinical stage \>= T2c
• Any performance status on the Eastern Cooperative Oncology Group (ECOG)
• Men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation
• Bone scan without evidence of skeletal metastases
• Skeletal x-ray film or MRI confirmation of absent skeletal metastases if bone scan findings are equivocal
• 3Tesla (T) multiparametric MRI of the prostate performed at City of Hope (COH) within 6 week time period prior to surgery; MRI without evidence of bladder neck involvement, rectal wall involvement, or pelvic lymphadenopathy with no nodes \> 1 cm
• White blood cell (WBC) within normal limits
• Hemoglobin (hgb) \> 10 G/dL
• Platelet count (PLT) \> 100 K/uL
• Creatinine clearance within normal limits
• Serum glutamic oxaloacetic transaminase (SGOT) \< 1.5 x upper limit of normal (ULN)
• Serum glutamate pyruvate transaminase (SGPT) \< 1.5 x ULN
• Bilirubin \< 1.5 x ULN
• All subjects must have the ability to understand and the willingness to sign a written informed consent
• Patients should not have any uncontrolled illness including ongoing or active infection
• Prior treatment of prostate cancer including brachytherapy, radiation therapy, cryosurgery, high-intensity focused ultrasound (HIFU), or vaccine therapy
• Prior pelvic surgery or radiation
• Urinary incontinence requiring condom catheter use or \>= 1 pad/day
• Prior anti-incontinence surgery
• Use of neoadjuvant hormonal manipulation
• History of active co-existing non-prostatic malignancies except basal cell skin cancer or squamous cell skin cancer
• Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study